Modulation of gamma globin genes expression by histone deacetylase inhibitors: An in vitro study

Luisa Ronzoni, Laura Sonzogni, Gianluca Fossati, Daniela Modena, Elena Trombetta, Laura Porretti, Maria Domenica Cappellini

Research output: Contribution to journalArticle

Abstract

Induction of fetal haemoglobin (HbF) is a promising therapeutic approach for the treatment of β-thalassaemia and sickle cell disease (SCD). Several pharmacological agents, such as hydroxycarbamide (HC) and butyrates, have been shown to induce the γ-globin genes (HBG1, HBG2). However, their therapeutic use is limited due to weak efficacy and an inhibitory effect on erythroid differentiation. Thus, more effective agents are needed. The histone deacetylase (HDAC) inhibitors are potential therapeutic haemoglobin (Hb) inducers able to modulate gene expression through pleiotropic mechanisms. We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC. We used an in vitro erythropoiesis model derived from peripheral CD34+ cells of healthy volunteers and SCD donors. GVS effects on erythroid proliferation and differentiation and on Hb synthesis were investigated. We found that GVS at high concentrations delayed erythroid differentiation with no specific effect on HBG1/2 transcription. At a low concentration (1 nmol/l), GVS induced Hb production with no effects on cells proliferation and differentiation. The efficacy of GVS 1 mol/l in Hb induction in vitro was comparable to that of HC and butyrate. Our results support the evaluation of GVS as a new candidate molecule for the treatment of the haemoglobinophathies due to its positive effects on haemoglobin production at low and non-toxic concentrations.

Original languageEnglish
Pages (from-to)714-721
Number of pages8
JournalBritish Journal of Haematology
Volume165
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

gamma-Globins
Histone Deacetylase Inhibitors
Hemoglobins
Gene Expression
Butyrates
Erythropoiesis
Sickle Cell Anemia
Fetal Hemoglobin
Thalassemia
Butyric Acid
Globins
Therapeutic Uses
Therapeutics
In Vitro Techniques
givinostat
Cell Differentiation
Healthy Volunteers
Cell Proliferation
Tissue Donors
Pharmacology

Keywords

  • Fetal haemoglobin induction
  • Globin gene transcription
  • Histone deacetylase inhibitor
  • Sickle cell disease
  • β-thalassaemia

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Modulation of gamma globin genes expression by histone deacetylase inhibitors : An in vitro study. / Ronzoni, Luisa; Sonzogni, Laura; Fossati, Gianluca; Modena, Daniela; Trombetta, Elena; Porretti, Laura; Cappellini, Maria Domenica.

In: British Journal of Haematology, Vol. 165, No. 5, 2014, p. 714-721.

Research output: Contribution to journalArticle

Ronzoni, Luisa ; Sonzogni, Laura ; Fossati, Gianluca ; Modena, Daniela ; Trombetta, Elena ; Porretti, Laura ; Cappellini, Maria Domenica. / Modulation of gamma globin genes expression by histone deacetylase inhibitors : An in vitro study. In: British Journal of Haematology. 2014 ; Vol. 165, No. 5. pp. 714-721.
@article{7201206847b3455bb5ae3c43d75ac64b,
title = "Modulation of gamma globin genes expression by histone deacetylase inhibitors: An in vitro study",
abstract = "Induction of fetal haemoglobin (HbF) is a promising therapeutic approach for the treatment of β-thalassaemia and sickle cell disease (SCD). Several pharmacological agents, such as hydroxycarbamide (HC) and butyrates, have been shown to induce the γ-globin genes (HBG1, HBG2). However, their therapeutic use is limited due to weak efficacy and an inhibitory effect on erythroid differentiation. Thus, more effective agents are needed. The histone deacetylase (HDAC) inhibitors are potential therapeutic haemoglobin (Hb) inducers able to modulate gene expression through pleiotropic mechanisms. We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC. We used an in vitro erythropoiesis model derived from peripheral CD34+ cells of healthy volunteers and SCD donors. GVS effects on erythroid proliferation and differentiation and on Hb synthesis were investigated. We found that GVS at high concentrations delayed erythroid differentiation with no specific effect on HBG1/2 transcription. At a low concentration (1 nmol/l), GVS induced Hb production with no effects on cells proliferation and differentiation. The efficacy of GVS 1 mol/l in Hb induction in vitro was comparable to that of HC and butyrate. Our results support the evaluation of GVS as a new candidate molecule for the treatment of the haemoglobinophathies due to its positive effects on haemoglobin production at low and non-toxic concentrations.",
keywords = "Fetal haemoglobin induction, Globin gene transcription, Histone deacetylase inhibitor, Sickle cell disease, β-thalassaemia",
author = "Luisa Ronzoni and Laura Sonzogni and Gianluca Fossati and Daniela Modena and Elena Trombetta and Laura Porretti and Cappellini, {Maria Domenica}",
year = "2014",
doi = "10.1111/bjh.12814",
language = "English",
volume = "165",
pages = "714--721",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Modulation of gamma globin genes expression by histone deacetylase inhibitors

T2 - An in vitro study

AU - Ronzoni, Luisa

AU - Sonzogni, Laura

AU - Fossati, Gianluca

AU - Modena, Daniela

AU - Trombetta, Elena

AU - Porretti, Laura

AU - Cappellini, Maria Domenica

PY - 2014

Y1 - 2014

N2 - Induction of fetal haemoglobin (HbF) is a promising therapeutic approach for the treatment of β-thalassaemia and sickle cell disease (SCD). Several pharmacological agents, such as hydroxycarbamide (HC) and butyrates, have been shown to induce the γ-globin genes (HBG1, HBG2). However, their therapeutic use is limited due to weak efficacy and an inhibitory effect on erythroid differentiation. Thus, more effective agents are needed. The histone deacetylase (HDAC) inhibitors are potential therapeutic haemoglobin (Hb) inducers able to modulate gene expression through pleiotropic mechanisms. We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC. We used an in vitro erythropoiesis model derived from peripheral CD34+ cells of healthy volunteers and SCD donors. GVS effects on erythroid proliferation and differentiation and on Hb synthesis were investigated. We found that GVS at high concentrations delayed erythroid differentiation with no specific effect on HBG1/2 transcription. At a low concentration (1 nmol/l), GVS induced Hb production with no effects on cells proliferation and differentiation. The efficacy of GVS 1 mol/l in Hb induction in vitro was comparable to that of HC and butyrate. Our results support the evaluation of GVS as a new candidate molecule for the treatment of the haemoglobinophathies due to its positive effects on haemoglobin production at low and non-toxic concentrations.

AB - Induction of fetal haemoglobin (HbF) is a promising therapeutic approach for the treatment of β-thalassaemia and sickle cell disease (SCD). Several pharmacological agents, such as hydroxycarbamide (HC) and butyrates, have been shown to induce the γ-globin genes (HBG1, HBG2). However, their therapeutic use is limited due to weak efficacy and an inhibitory effect on erythroid differentiation. Thus, more effective agents are needed. The histone deacetylase (HDAC) inhibitors are potential therapeutic haemoglobin (Hb) inducers able to modulate gene expression through pleiotropic mechanisms. We investigated the effects of a HDAC inhibitor, Givinostat (GVS), on erythropoiesis and haemoglobin synthesis and compared it with sodium butyrate and HC. We used an in vitro erythropoiesis model derived from peripheral CD34+ cells of healthy volunteers and SCD donors. GVS effects on erythroid proliferation and differentiation and on Hb synthesis were investigated. We found that GVS at high concentrations delayed erythroid differentiation with no specific effect on HBG1/2 transcription. At a low concentration (1 nmol/l), GVS induced Hb production with no effects on cells proliferation and differentiation. The efficacy of GVS 1 mol/l in Hb induction in vitro was comparable to that of HC and butyrate. Our results support the evaluation of GVS as a new candidate molecule for the treatment of the haemoglobinophathies due to its positive effects on haemoglobin production at low and non-toxic concentrations.

KW - Fetal haemoglobin induction

KW - Globin gene transcription

KW - Histone deacetylase inhibitor

KW - Sickle cell disease

KW - β-thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=84900498831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900498831&partnerID=8YFLogxK

U2 - 10.1111/bjh.12814

DO - 10.1111/bjh.12814

M3 - Article

C2 - 24606390

AN - SCOPUS:84900498831

VL - 165

SP - 714

EP - 721

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -